BioVersys AG

BioVersys AG is a privately owned clinical stage Swiss pharmaceutical company focusing on research and development of small molecules acting on novel bacterial targets with applications in antimicrobial resistance (AMR) and targeted microbiome modulation. BioVersys addresses high unmet medical needs with new treatments against life-threatening resistant bacterial infections and bacteria-exacerbated microbiome disorders. Our most advanced research and development programs address nosocomial infections of Acinetobacter baumannii (BV100, Phase 2), and tuberculosis (BVL-GSK098, Phase 2a) in collaboration with GlaxoSmithKline (GSK) and a consortium of the University of Lille.